Table 2.

Overview of randomized controlled trials on impact of CRC screening: results on all-cause and CRC-specific mortality (Intention-to-screen analyses ^a).

Studies	Screening Group			Control Group			All-Cause Mortality Rate Ratio (95 CI%) b	CRC-Specific Mortality Rate Ratio (95 CI%) b
	All-Cause Deaths	CRC-Specific Deaths	Total Person-Years of Observation	All-Cause Deaths	CRC-Specific Deaths	Total Person-Years of Observation
FOBT
A Shaukat 2013 [52]	22,076	437	951,047	10,944	295	469,897	1.00 (0.97, 1.02)	0.73 (0.63, 0.85)
A Shaukat 2021 [51]	22,474	786	605,023	22,535	851	603,953	1.00 (0.98, 1.01)	0.92 (0.84, 1.02)
E Lindholm 2008 [54]	10,591	252	471,072	10,432	300	471,980	1.02 (0.99, 1.04)	0.84 (0.71, 1.00)
J H Scholefield 2012 [49]	40,681	1176	1,296,712	40,550	1300	1,296,614	1.00 (0.99, 1.02)	0.90 (0.84, 0.98)
J Pitkäniemi 2015 [56]	8000	170	805,480	7963	164	805,693	1.00 (0.97, 1.04)	1.04 (0.84, 1.28)
Meta-analysis:
No. of studies							5	5
Pooled estimate							1.00 (0.99, 1.01)	0.88 (0.80, 0.96)
Test for overall effect: P							0.65	0.005
Heterogeneity: I2 (%)/Tau2/P							0/0.00/0.74	59/0.01/0.04
FS
E Thiis-Evensen 2013 [57]	188	1	8441	151	7	8997	1.33 (1.07, 1.64)	0.15 (0.02, 1.24)
C Senore 2022 [50]	3062	122	296,730	3155	157	295,013	0.96 (0.92, 1.01)	0.77 (0.61, 0.98)
P F Pinsky 2019 [55]	22,562	416	1,234,900	22,652	546	1,222,450	0.99 (0.97, 1.00)	0.75 (0.66, 0.86)
W Atkin 2017 [48]	13,279	353	902,198	26,409	996	1,780,738	0.99 (0.97, 1.01)	0.70 (0.62, 0.79)
Ø Holme 2018 [53]	3809	122	291,075	13,433	530	1,114,581	1.09 (1.05, 1.13)	0.88 (0.72, 1.07)
Meta-analysis:
No. of studies							5	5
Pooled estimate							1.02 (0.97, 1.06)	0.76 (0.68, 0.84)
Test for overall effect: P							0.46	<0.001
Heterogeneity: I2 (%)/Tau2/P							88/0.00/<0.001	35/0.00/0.19

^a Intention-to-screen analyses: including all individuals as randomized. Not be adjusted by compliance. ^b Control group was used as the reference.